干眼症市场规模、份额和成长分析（按产品类型、配方类型、分销管道和地区）- 2025-2032 年产业预测

预计干眼症市场规模在 2023 年将达到 56 亿美元，并从 2024 年的 60.5 亿美元增长到 2032 年的 112.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.1%。

全球干眼症 (DED) 市场的发展受到老年族群，尤其是女性族群中干眼症发病率不断上升的推动。瘢痕性角膜炎和泪液功能障碍综合症等症状凸显了这种眼表疾病的重要性，它影响着相当一部分老年人口。世界卫生组织 (WHO) 预测，2015 年至 2050 年期间，60 岁或以上人口的比例将几乎翻一番，从 12% 增至 22%，其中 80%居住在中低收入国家，对有效的干眼症治疗的需求将日益增长。在这个快速成长的市场中，加强临床试验和研究对于提高药物采用率至关重要，特别是随着老年人群越来越容易患上眼部疾病。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

干眼症市场规模（依产品类型）：及复合年增长率（2025-2032）

• 市场概况
• Cyclosporine
• 皮质类固醇
• 利菲特罗
• 眼部润滑剂
• 泪点塞
• 其他的

干眼症市场规模（按配方类型和复合年增长率） (2025-2032)

• 市场概况
• 液体
• 凝胶
• 软膏
• 其他的

干眼症市场规模（依通路）：及复合年增长率（2025-2032）

• 市场概况
• 医院药房
• 零售药局
• 超级市场/大卖场
• 其他商店
• 网路药局

干眼症市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Novartis（Switzerland）
• Allergan（Ireland）
• AbbVie（US）
• Johnson & Johnson（US）
• Bausch+Lomb（Canada）
• Rohto Pharmaceutical Co., Ltd.（Japan）
• Oculis（Switzerland）
• Visus Therapeutics（US）
• Kala Pharmaceuticals（US）
• Sun Pharmaceutical Industries Ltd.（India）
• Prestige Consumer Healthcare（US）
• Similasan Corporation（Switzerland）
• Scope Ophthalmics（UK）
• Thea Pharmaceuticals（France）
• Ursapharm Arzneimittel GmbH（Germany）
• EyeGate Pharmaceuticals, Inc.（US）
• Aldeyra Therapeutics（US）
• QuidelOrtho Corporation（US）

结论和建议

Dry Eye Disease Market size was valued at USD 5.6 billion in 2023 and is poised to grow from USD 6.05 billion in 2024 to USD 11.29 billion by 2032, growing at a CAGR of 8.1% during the forecast period (2025-2032).

The global dry eye disease (DED) market is poised for growth, driven by an increasing prevalence of the condition among older adults, particularly women. Conditions like keratitis sicca and dysfunctional tear syndrome underline the significance of this ocular surface disease, which affects a substantial segment of the aging population. With the World Health Organization projecting that individuals aged 60 and above will nearly double from 12% to 22% between 2015 and 2050, and with a striking 80% of this demographic residing in low- and middle-income countries, the demand for effective dry eye treatments is set to rise. Enhanced clinical trials and research are essential to boost drug penetration in this burgeoning market, particularly as the elderly population becomes more vulnerable to eye disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Dry Eye Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Dry Eye Disease Market Segments Analysis

Global Dry Eye Disease Market is segmented by Product Type, Formulation Type, Distribution Channel: and region. Based on Product Type, the market is segmented into Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Others. Based on Formulation Type, the market is segmented into Liquid, Gel, Ointment and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Supermarket/Hypermarket, Other Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Dry Eye Disease Market

The dry eye disease market, encompassing conditions like keratoconjunctivitis sicca (KCS), serves an extensive population, with around 360 million affected globally. This prevalent ocular disorder manifests through symptoms of dryness, irritation, redness, fatigue, and blurred vision. The incidence is not limited to age, as it is increasingly observed in both younger and older demographics, largely attributed to heightened screen exposure, poor dietary habits, growing contact lens usage, and more frequent LASIK surgeries. As individuals age, the lachrymal glands' tear production diminishes, leading to dry eye complaints. Hence, the escalating prevalence of dry eye disease, particularly among aging populations, significantly propels the demand for dry eye treatments in the market.

Restraints in the Dry Eye Disease Market

The Dry Eye Disease market faces significant restraints due to a lack of public awareness regarding eye health. Many individuals do not recognize the importance of seeking treatment for common dry eye symptoms, which are often misconstrued and can be effectively managed with accurate diagnosis and appropriate medications. Typically, patients only consult ophthalmologists when experiencing severe discomfort, leading to the underdiagnosis of symptoms like redness and burning. This lack of recognition limits the pool of individuals who could benefit from prescription treatments. A UK survey revealed that one in four adults neglects biannual eye examinations as recommended, indicating a pervasive ignorance around eye health, particularly among children.

Market Trends of the Dry Eye Disease Market

The dry eye disease market is experiencing a notable upward trend characterized by heightened investment in research and development, culminating in successful clinical trials and a surge in new product approvals. Pharmaceutical companies like Aldeyra Therapeutics, Inc. are leading the charge with promising candidates like Reproxalap, currently in Phase III trials, setting a precedent for innovation. This influx of clinical activity not only fosters competitive differentiation but also enhances the treatment landscape, thereby significantly boosting revenue potential. Such strategic initiatives reflect a commitment to addressing unmet needs and solidifying market presence, positioning the dry eye disease market for robust growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Dry Eye Disease Market Size by Product Type: & CAGR (2025-2032)

• Market Overview
• Cyclosporine
• Corticosteroids
• Lifitegrast
• Ocular Lubricant
• Punctal Plugs
• Others

Global Dry Eye Disease Market Size by Formulation Type: & CAGR (2025-2032)

• Market Overview
• Liquid
• Gel
• Ointment
• Others

Global Dry Eye Disease Market Size by Distribution Channel: & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Supermarket/Hypermarket
• Other Stores
• Online Pharmacies

Global Dry Eye Disease Market Size & CAGR (2025-2032)

• North America (Product Type:, Formulation Type:, Distribution Channel:)
  • US
  • Canada
• Europe (Product Type:, Formulation Type:, Distribution Channel:)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type:, Formulation Type:, Distribution Channel:)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type:, Formulation Type:, Distribution Channel:)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type:, Formulation Type:, Distribution Channel:)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rohto Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oculis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Visus Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kala Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prestige Consumer Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Similasan Corporation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Scope Ophthalmics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thea Pharmaceuticals (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ursapharm Arzneimittel GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyeGate Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aldeyra Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuidelOrtho Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations